drugset / Trial / NCT00234975
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
Timeline
- Start
- 2002-10
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lopinavir | Other / unclassified | 400 mg | — |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |